Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market and a regional leader in hospital ...

By CH Unnikrsihnan Drug maker and researcher Glenmark Pharmaceuticals Ltd's new biological drug candidate Bi-Specific ...

As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving immunotherapy.

Zydus has launched Tishtha, an affordable biosimilar of nivolumab, at nearly one-fourth the original price. Approved by the ...

The launch follows a Delhi High Court nod allowing sales of the cancer drug biosimilar ahead of patent expiry in May 2026.

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

At the end of last year, an Ebola disease outbreak in the Democratic Republic of Congo’s Kasai province was officially declared over.

OpenX Technologies, Inc., one of the world's leading omnichannel supply-side platforms, today announced two additions to its ...

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

Get all latest & breaking news on Nipah Virus. Watch videos, top stories and articles on Nipah Virus at moneycontrol.com.

The COVID vaccine program for children 6 months old and up now uses a shared decision-making approach because children have had fewer than 1,000 severe illnesses since 2020, and new virus variants spr ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.